Childhood Acute Lymphoblastic Leukemia (ALL): Diagnosis, Treatment, and Management

Abstract Childhood Acute Lymphoblastic Leukemia (ALL) is the most common pediatric malignancy, accounting for approximately 25% of childhood cancers. With advancements in diagnostic tools, treatment protocols, and supportive care, survival rates for ALL have significantly improved, reaching nearly 90% in high-income countries. This review discusses the current approaches to diagnosing, treating, and managing childhood ALL, highlighting recent advancements in genomics, immunotherapy, and risk stratification strategies that continue to shape patient outcomes.